Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target
T-cell exhaustion contributes to immunotherapy failure in chronic lymphocytic leukemia (CLL). Here, we analyze T cells from CLL patients’ blood, bone marrow, and lymph nodes, as well as from a CLL mouse model, using single-cell RNA sequencing, mass cytometry, and tissue imaging. T cells in CLL lymph...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
07 August 2025
|
| In: |
Nature Communications
Year: 2025, Volume: 16, Pages: 1-22 |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-025-61822-x |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41467-025-61822-x Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41467-025-61822-x |
| Author Notes: | L. Llaó-Cid, J.K.L. Wong, I. Fernandez Botana, Y. Paul, M. Wierz, L.-M. Pilger, A. Floerchinger, C.L. Tan, S. Gonder, G. Pagano, M. Chazotte, K. Bestak, C. Schifflers, M. Iskar, T. Roider, F. Czernilofsky, P.-M. Bruch, J.P. Mallm, A. Cosma, D.E. Campton, E. Gerhard-Hartmann, A. Rosenwald, D. Colomer, E. Campo, D. Schapiro, E.W. Green, S. Dietrich, P. Lichter, E. Moussay, J. Paggetti, M. Zapatka & M. Seiffert |
| Summary: | T-cell exhaustion contributes to immunotherapy failure in chronic lymphocytic leukemia (CLL). Here, we analyze T cells from CLL patients’ blood, bone marrow, and lymph nodes, as well as from a CLL mouse model, using single-cell RNA sequencing, mass cytometry, and tissue imaging. T cells in CLL lymph nodes show the most distinct profiles, with accumulation of regulatory T cells and CD8+ T cells in various exhaustion states, including precursor (TPEX) and terminally exhausted (TEX) cells. Integration of T-cell receptor sequencing data and use of the predicTCR classifier suggest an enrichment of CLL-reactive T cells in lymph nodes. Interactome studies reveal potential immunotherapy targets, notably galectin-9, a TIM3 ligand. Inhibiting galectin-9 in mice reduces disease progression and TIM3+ T cells. Galectin-9 expression also correlates with worse survival in CLL and other cancers, suggesting its role in immune evasion and potential as a therapeutic target. |
|---|---|
| Item Description: | Online veröffentlicht: 07. August 2025 Gesehen am 21.01.2026 |
| Physical Description: | Online Resource |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-025-61822-x |